Abstract
Many reports of Autologous Stem Cell Transplant (ASCT) in patients with multiple myeloma are available in the literature to determine safety for patients with hemodialysis-dependent End-Stage Renal Disease (ESRD). However, very few report the safety of high-dose chemotherapy followed by ASCT in the context of lymphoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have